Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.43 |
| ▸ | CTSL | P07711 | 6/20 | 0.43 |
| ▸ | CTSB | P07858 | 5/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 7/20 | 0.41 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | KYNU | Q16719 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263479 | 0.92 | CTSL (0.41) | CTSSCTSLCTSBATMSYK | |
| SCHEMBL262927 | 0.88 | SYK (0.47) | CTSSCTSLCTSBATMSYK | |
| SCHEMBL2793720 | 0.84 | CTSS (0.41) | CTSSCTSLCTSBATMSYK | |
| SCHEMBL5724195 | 0.83 | SYK (0.52) | CTSSCTSLCTSBATMSYK | |
| SCHEMBL264163 | 0.83 | CTSL (0.40) | CTSSCTSLCTSBATMSYK | |
| SCHEMBL23455702 | 0.82 | PPARA (0.51) | CTSSCTSLCTSBATMSYK | |
| SCHEMBL5724014 | 0.82 | ATM (0.50) | CTSSCTSLCTSBATMSYK | |
| SCHEMBL10045788 | 0.82 | PPARA (0.51) | CTSSCTSLCTSBATMSYK | |
| SCHEMBL261847 | 0.82 | SYK (0.48) | CTSSCTSLCTSBATMSYK | |
| SCHEMBL15924777 | 0.81 | KYNU (0.53) | CTSSCTSLCTSBATMSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168131-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-07-01 | — | — | US | disclosed |
| WO-2010063662-A1 | N-{[(IR,4S,6R-3-(2-PYRIDINYLCARBONYL)-3-AZABICYCLO [4.1.0] HEPT-4-YL] METHYL}-2-HETEROARYLAMINE DERIVATIVES AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168131-A1 | NOVEL COMPOUNDS | HTR3B, HNMT, TPMT | CTSS 1047/4885CTSL 1788/4885CTSB 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.